Design and Synthesis of Enediyne containing Combretastatin A-4 Analogues as Antimitosis Agents

碩士 === 國立中山大學 === 化學系研究所 === 98 === We designed a new series of enediyne and their derivatives, and evaluating for their growth inhibition activity against human tumor cell lines. This dissertation is composed of two parts. First, compounds 6c, 6e, 6g and 7g displayed good growth inhibition activity...

Full description

Bibliographic Details
Main Authors: Chen-Yi Tseng, 曾貞宜
Other Authors: Ming-jung Wu
Format: Others
Language:zh-TW
Published: 2010
Online Access:http://ndltd.ncl.edu.tw/handle/87317551054580236019
id ndltd-TW-098NSYS5065011
record_format oai_dc
spelling ndltd-TW-098NSYS50650112015-10-13T18:35:39Z http://ndltd.ncl.edu.tw/handle/87317551054580236019 Design and Synthesis of Enediyne containing Combretastatin A-4 Analogues as Antimitosis Agents 設計與合成具有烯雙炔結構之ombretastatinA-4衍生物為抗有絲分裂試劑 Chen-Yi Tseng 曾貞宜 碩士 國立中山大學 化學系研究所 98 We designed a new series of enediyne and their derivatives, and evaluating for their growth inhibition activity against human tumor cell lines. This dissertation is composed of two parts. First, compounds 6c, 6e, 6g and 7g displayed good growth inhibition activity against A549 (non-small-cell lung cancer), AGS (human stomach adenocarcinoma), PC-3 (prostate cancer), BT483 (breast carcinomas), HeLa (human cervical epithelioid carcinoma), OVCA (ovarian cancer cell line), SKHep (hepatocellular carcinoma), H460 (human lung cancer cell line) and SW620 (Human Colorectal Cancer Cell Line), especially compound 7g is better, and its average IC50 is 8.79μM. Second, compounds 25a and 26 displayed better growth inhibition activity against HeLa (human cervical epithelioid carcinoma), OVCA (ovarian cancer cell line), AGS (human stomach adenocarcinoma) and H460 (human lung cancer cell line), and their average IC50 are10.82 and 11.08 μM. Ming-jung Wu 吳明忠 2010 學位論文 ; thesis 182 zh-TW
collection NDLTD
language zh-TW
format Others
sources NDLTD
description 碩士 === 國立中山大學 === 化學系研究所 === 98 === We designed a new series of enediyne and their derivatives, and evaluating for their growth inhibition activity against human tumor cell lines. This dissertation is composed of two parts. First, compounds 6c, 6e, 6g and 7g displayed good growth inhibition activity against A549 (non-small-cell lung cancer), AGS (human stomach adenocarcinoma), PC-3 (prostate cancer), BT483 (breast carcinomas), HeLa (human cervical epithelioid carcinoma), OVCA (ovarian cancer cell line), SKHep (hepatocellular carcinoma), H460 (human lung cancer cell line) and SW620 (Human Colorectal Cancer Cell Line), especially compound 7g is better, and its average IC50 is 8.79μM. Second, compounds 25a and 26 displayed better growth inhibition activity against HeLa (human cervical epithelioid carcinoma), OVCA (ovarian cancer cell line), AGS (human stomach adenocarcinoma) and H460 (human lung cancer cell line), and their average IC50 are10.82 and 11.08 μM.
author2 Ming-jung Wu
author_facet Ming-jung Wu
Chen-Yi Tseng
曾貞宜
author Chen-Yi Tseng
曾貞宜
spellingShingle Chen-Yi Tseng
曾貞宜
Design and Synthesis of Enediyne containing Combretastatin A-4 Analogues as Antimitosis Agents
author_sort Chen-Yi Tseng
title Design and Synthesis of Enediyne containing Combretastatin A-4 Analogues as Antimitosis Agents
title_short Design and Synthesis of Enediyne containing Combretastatin A-4 Analogues as Antimitosis Agents
title_full Design and Synthesis of Enediyne containing Combretastatin A-4 Analogues as Antimitosis Agents
title_fullStr Design and Synthesis of Enediyne containing Combretastatin A-4 Analogues as Antimitosis Agents
title_full_unstemmed Design and Synthesis of Enediyne containing Combretastatin A-4 Analogues as Antimitosis Agents
title_sort design and synthesis of enediyne containing combretastatin a-4 analogues as antimitosis agents
publishDate 2010
url http://ndltd.ncl.edu.tw/handle/87317551054580236019
work_keys_str_mv AT chenyitseng designandsynthesisofenediynecontainingcombretastatina4analoguesasantimitosisagents
AT céngzhēnyí designandsynthesisofenediynecontainingcombretastatina4analoguesasantimitosisagents
AT chenyitseng shèjìyǔhéchéngjùyǒuxīshuāngguìjiégòuzhīombretastatina4yǎnshēngwùwèikàngyǒusīfēnlièshìjì
AT céngzhēnyí shèjìyǔhéchéngjùyǒuxīshuāngguìjiégòuzhīombretastatina4yǎnshēngwùwèikàngyǒusīfēnlièshìjì
_version_ 1718035436149932032